Encountering unpredicted off-target effects of pharmacological inhibitors
1Department of Biochemistry, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan.
Abstract:
With the emergence of chemical biology, the use of pharmacological inhibitors in biological research has been expanding. SP600125 is a low-molecular weight compound that has been widely used to inhibit c-Jun-N-terminal kinase (JNK). A recent publication by Tanemura et al. (J. Biochem. 145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110δ), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110α and p110γ. Here, I discuss what we learn from such unpredicted off-target effects of pharmacological inhibitors.
More Related Videos
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Idiosyncratic Reactions
Drug toxicity: Drug–Drug Interaction
Desensitization and Tachyphylaxis
Several...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu


